Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $8.00

Pyxis Oncology (NASDAQ:PYXS) had its price target upped by HC Wainwright from $7.00 to $8.00 in a research note published on Thursday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

PYXS has been the topic of a number of other reports. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Leerink Partners reduced their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, July 2nd. Wells Fargo & Company lifted their price target on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday. Weiss Ratings lowered shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Finally, Wedbush upped their price target on Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Pyxis Oncology Stock Down 1.8%

Shares of PYXS stock opened at $3.21 on Thursday. The stock has a 50-day simple moving average of $3.03 and a 200 day simple moving average of $2.24. The stock has a market capitalization of $267.75 million, a P/E ratio of -2.28 and a beta of 1.34. Pyxis Oncology has a fifty-two week low of $1.03 and a fifty-two week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, sell-side analysts anticipate that Pyxis Oncology will post -1.21 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Maia Wealth LLC acquired a new position in shares of Pyxis Oncology in the fourth quarter worth about $25,000. Engineers Gate Manager LP purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $26,000. Fox Run Management L.L.C. purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $26,000. XTX Topco Ltd acquired a new position in Pyxis Oncology in the 2nd quarter worth approximately $40,000. Finally, LPL Financial LLC boosted its stake in Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after purchasing an additional 21,100 shares during the period. Institutional investors and hedge funds own 39.07% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.